Cargando…
Rapamycin and Low-dose IL-2 Mediate an Immunosuppressive Microenvironment to Inhibit Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is a condition that becomes more common with age and manifests itself primarily as the expansion of the prostate and surrounding tissues. However, to date, the etiology of BPH remains unclear. In this respect, we performed single-cell RNA sequencing of prostate tra...
Autores principales: | Cao, Tianyu, Xie, Feng, Shi, Youwei, Xu, Junhao, Liu, Yi, Cui, Di, Zhang, Fang, Lin, Lihui, Li, Weize, Gao, Yanting, Ruan, Yuan, Wang, Xiaohai, Zhu, Yiping, Han, Bangmin, Xia, Shujie, Guo, Wenhuan, Li, Bin, Jing, Yifeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367549/ https://www.ncbi.nlm.nih.gov/pubmed/37497009 http://dx.doi.org/10.7150/ijbs.85089 |
Ejemplares similares
-
A Modified Technique of Thulium Laser Enucleation for Benign Prostatic Hyperplasia With Non-morcellator Approach
por: Jing, Yifeng, et al.
Publicado: (2021) -
Tissue microenvironment and benign prostatic hyperplasia
por: Wei, Xing, et al.
Publicado: (2019) -
Targeting ADT-Induced Activation of the E3 Ubiquitin Ligase Siah2 to Delay the Occurrence of Castration-Resistant Prostate Cancer
por: Yan, Tingmang, et al.
Publicado: (2021) -
Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats
por: Lesovaya, Ekaterina A., et al.
Publicado: (2015) -
Pao Pereira extract suppresses benign prostatic hyperplasia by inhibiting inflammation-associated NFκB signaling
por: Dong, Yu, et al.
Publicado: (2020)